PT - JOURNAL ARTICLE AU - Brit Mollenhauer AU - Mohammed Dakna AU - Tzu-Ying Liu AU - Douglas Galasko AU - Tatiana Foroud AU - Henrik Zetterberg AU - Sebastian Schade AU - Roland Gera AU - Wenting Wang AU - Feng Gao AU - Niels Kruse AU - Mark Frasier AU - Lana M. Chahine AU - Christopher S. Coffey AU - Andrew B. Singleton AU - Tanya Simuni AU - Daniel Weintraub AU - John Seibyl AU - Arthur W. Toga AU - Caroline M. Tanner AU - Karl Kieburtz AU - Kenneth Marek AU - Andrew Siderowf AU - Jesse M. Cedarbaum AU - Samantha J. Hutten AU - Claudia Trenkwalder AU - Danielle Graham TI - Cross-Sectional and Longitudinal Validation of Serum Neurofilament Light Chain (NfL) as a Biomarker of Parkinson’s Disease Progression AID - 10.1101/762237 DP - 2019 Jan 01 TA - bioRxiv PG - 762237 4099 - http://biorxiv.org/content/early/2019/09/11/762237.short 4100 - http://biorxiv.org/content/early/2019/09/11/762237.full AB - Background Alterations in neurofilament light chain (NfL), reflecting axonal damage, have been proposed as a biomarker for neurological disorders including Parkinson’s disease (PD).Methods We measured NfL concentrations by immunoassay in (1) a set of longitudinal CSF samples from 82 PD, 14 other neurodegenerative disorders (OND), and 53 healthy controls (HC); (2) A cross-sectional cohort with paired CSF and serum samples from subjects with 151 PD, 344 OND, and 20 HC, and (3a) a large longitudinal validation cohort with serum samples from 375 PD, 178 HC, and 57 prodromal Lewy Body disorder with hyposmia or isolated REM sleep behaviour disorder (iRBD), (3b) 216 symptomatic and 298 asymptomatic LRRK2, GBA, and SNCA mutation carriers in the Parkinson’s Progression Markers Initiative (PPMI). Mean differences in serum NfL levels between diagnostic groups, and correlation with motor signs, cognitive measures and dopamine transporter imaging, were assessed. Linear mixed effects models were used to assess longitudinal changes in log10 (NfL) in relation to demographic, clinical, and imaging variables.Findings In the longitudinal cohort (1) NfL in CSF increased over time and was significantly positively correlated with MDS-UPDRS III motor and total scores in the PD group (p=0·0231 and 0·0081). In the cross-sectional cohort (2) the paired CSF and serum NfL samples were highly correlated (Spearman’s rank . In the large validation cohort (3a) mean baseline serum NfL was higher in PD (13 ±7·2pg/ml), hyposmics (15±15·1pg/ml), and iRBD (17±8pg/ml) compared with HC (12±6·7pg/ml) but was highest in the seven OND cases (18±7pg/ml). In the genetic cohort (3b), serum NfL levels were lower in asymptomatic than in symptomatic mutation carriers. There was a significant (age-adjusted) longitudinal increase in serum NfL in PD compared with HC. Serum NfL values were significantly positively associated with longitudinal MDS-UPDRS motor and total scores, as well as age.Interpretation We identified NfL as the first blood-based PD progression biomarker. NfL levels in serum samples are increased in PD compared to HC, increase significantly over time in PD, and correlate with a clinical measure of disease severity. Although the specificity of NfL in PD is low and additional, more specific biomarkers are needed, serum NfL is the first blood-based biomarker candidate that could support disease stratification (PD vs. OND), track clinical progression, and might be used to assess responsiveness to neuroprotective treatments.